Harrow (HROW) Other financing activities (2014 - 2026)
Harrow's (HROW) quarterly Other financing activities came in at $25000.0 in Q1 2026, up 8.7% year-on-year from $23000.0 in Q1 2025, and down 86.11% quarter-over-quarter from $180000.0 in Q4 2025.
Harrow (HROW) Other financing activities (2014 - 2026) Analysis & Trends
Harrow's Other financing activities history runs 12 years deep, the most recent figure standing at $25000.0 for Q1 2026.
- On a quarterly basis, Other financing activities rose 8.7% year-over-year to $25000.0 in Q1 2026; TTM through Mar 2026 was $469000.0, a 40.25% decrease from a year earlier, with the FY2025 full-year figure at $467000.0, down 57.93% from the prior year.
- Other financing activities declined to $25000.0 in Q1 2026 per HROW's latest filing, from $180000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $73.2 million in Q4 2023 and bottomed at $3000.0 in Q2 2022.
- The 5-year median for Other financing activities is $155000.0 (2023), against an average of $6.1 million.
- Across the five-year window, Other financing activities jumped 6200.0% in 2023 and tumbled 99.86% in 2024, its largest moves.
- Year by year, Other financing activities stood at $22.6 million in 2022, then jumped by 223.19% to $73.2 million in 2023, then tumbled by 99.86% to $105000.0 in 2024, then jumped by 71.43% to $180000.0 in 2025, then plunged by 86.11% to $25000.0 in 2026.
- Per Business Quant, the three latest HROW Other financing activities figures stand at $25000.0 (Q1 2026), $180000.0 (Q4 2025), and $162000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25,000.00 |
| Mar 31, 2026 | 25,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Sep 30, 2025 | 162,000.00 |
| Sep 30, 2025 | 162,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Sep 30, 2024 | 484,000.00 |
| Sep 30, 2024 | 484,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Jun 30, 2024 | 173,000.00 |
| Mar 31, 2024 | 348,000.00 |
| Mar 31, 2024 | 348,000.00 |
| Dec 31, 2023 | 73.20 Mn |
| Dec 31, 2023 | 73.20 Mn |